BioCentury
ARTICLE | Clinical News

Alteon preclinical data

January 29, 2001 8:00 AM UTC

ALT researchers and colleagues published in Diabetologia that ALT-946 was more potent that ALT's lead product, Pimagedine aminoguanidine, in preventing advanced glycosylation end product protein cross...